Announcements Trials
Browse Landscape

Status

Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Melanoma 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Aftercare × Dermatologic × Clear all
NCT07347392 2026-01-16

DOSCA-2

University of Aarhus

Enrolling by invitation
2,900 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT01018004 2013-08-26

Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma

National Cancer Institute (NCI)

Unknown
178 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡